CDH1, DLEC1 and SFRP5 Methylation Panel As a Prognostic Marker for Advanced Epithelial Ovarian Cancer

References

• Siegel RL , MillerKD , JemalA . Cancer statistics, 2016 . CA Cancer J. Clin.66 ( 1 ), 7 – 30 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Siegel RL , MillerKD , JemalA . Cancer statistics, 2017 . CA Cancer J. Clin.67 ( 1 ), 7 – 30 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Chiang YC , ChenCA , ChiangCJet al. Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan . J. Gynecol. Oncol.24 ( 4 ), 342 – 351 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Jayson GC , KohnEC , KitchenerHC , LedermannJA . Ovarian cancer . Lancet384 ( 9951 ), 1376 – 1388 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Banerjee S , KayeSB . New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential . Clin. Cancer Res.19 ( 5 ), 961 – 968 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Vaughan S , CowardJI , BastRCJret al. Rethinking ovarian cancer: recommendations for improving outcomes . Nat. Rev. Cancer.11 ( 10 ), 719 – 725 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Coleman RL , MonkBJ , SoodAK , HerzogTJ . Latest research and treatment of advanced-stage epithelial ovarian cancer . Nat. Rev. Clin. Oncol.10 ( 4 ), 211 – 224 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hiss D . Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways . J. Oncol. 2012 , 737981 ( 2012 ).
   PubMedGoogle Scholar
• Perren TJ , SwartAM , PfistererJet al. A Phase 3 trial of bevacizumab in ovarian cancer . N. Engl. J. Med.365 ( 26 ), 2484 – 2496 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Oza AM , CookAD , PfistererJet al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a Phase 3 randomised trial . Lancet Oncol.16 ( 8 ), 928 – 936 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Burger RA , BradyMF , BookmanMAet al. Incorporation of bevacizumab in the primary treatment of ovarian cancer . N. Engl. J. Med.365 ( 26 ), 2473 – 2483 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ledermann J , HarterP , GourleyCet al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer . N. Engl. J. Med.366 ( 15 ), 1382 – 1392 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mirza MR , MonkBJ , HerrstedtJet al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer . N. Engl. J. Med.375 ( 22 ), 2154 – 2164 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Marchetti C , LedermannJA , Benedetti PaniciP . An overview of early investigational therapies for chemoresistant ovarian cancer . Expert Opin. Investig. Drugs24 ( 9 ), 1163 – 1183 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kampan NC , MadondoMT , McNallyOM , QuinnM , PlebanskiM . Paclitaxel and its evolving role in the management of ovarian cancer . BioMed. Res. Int. 2015 , 413076 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Egger G , LiangG , AparicioA , JonesPA . Epigenetics in human disease and prospects for epigenetic therapy . Nature429 ( 6990 ), 457 – 463 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Huang YW , KuoCT , StonerK , HuangTH , WangLS . An overview of epigenetics and chemoprevention . FEBS Lett.585 ( 13 ), 2129 – 2136 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Palmirotta R , SilvestrisE , D’OronzoS , CardasciaA , SilvestrisF . Ovarian cancer: novel molecular aspects for clinical assessment . Crit. Rev. Oncol. Hematol.117 , 12 – 29 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Yoo CB , JonesPA . Epigenetic therapy of cancer: past, present and future . Nat. Rev. Drug Discov.5 ( 1 ), 37 – 50 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Herman JG , BaylinSB . Gene silencing in cancer in association with promoter hypermethylation . N. Engl. J. Med.349 ( 21 ), 2042 – 2054 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Chen CA , ChiangYC , ChangMCet al. Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas . Am. J. Transl. Res.7 ( 1 ), 139 – 152 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Prat J . Staging classification for cancer of the ovary, fallopian tube, and peritoneum . Int. J. Gynaecol. Obstet.124 ( 1 ), 1 – 5 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Fandy TE , HermanJG , KernsPet al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies . Blood114 ( 13 ), 2764 – 2773 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Moon DC , ChoiCH , LeeSMet al. Nuclear translocation of Acinetobacter baumannii transposase induces DNA methylation of CpG regions in the promoters of E-cadherin gene . PLoS ONE7 ( 6 ), e38974 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Xiao Q , ZhouD , RuckiAAet al. Cancer-associated fibroblasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic DNA methylation . Cancer Res.76 ( 18 ), 5395 – 5404 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ayadi W , Karray-HakimH , KhabirAet al. Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients . Anticancer Res.28 ( 4b ), 2161 – 2167 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Hong Q , LiY , ChenXet al. CDKN2B, SLC19A3 and DLEC1 promoter methylation alterations in the bone marrow of patients with acute myeloid leukemia during chemotherapy . Exp. Ther. Med.11 ( 5 ), 1901 – 1907 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Pastuszak-Lewandoska D , KordiakJ , AntczakAet al. Expression level and methylation status of three tumor suppressor genes, DLEC1, ITGA9 and MLH1, in non-small cell lung cancer . Med. Oncol.33 ( 7 ), 75 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Tian F , YipSP , KwongDL , LinZ , YangZ , WuVW . Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma . Cancer Epidemiol.37 ( 5 ), 708 – 713 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Corn PG , SmithBD , RuckdeschelES , DouglasD , BaylinSB , HermanJG . E-cadherin expression is silenced by 5′ CpG island methylation in acute leukemia . Clin. Cancer Res.6 ( 11 ), 4243 – 4248 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Cheng YY , YuJ , WongYPet al. Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer . Br. J. Cancer97 ( 7 ), 895 – 901 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Chung MT , SytwuHK , YanMDet al. Promoter methylation of SFRPs gene family in cervical cancer . Gynecol. Oncol.112 ( 2 ), 301 – 306 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Sogabe Y , SuzukiH , ToyotaMet al. Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma . Int. J. Oncol.32 ( 6 ), 1253 – 1261 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Zou H , MolinaJR , HarringtonJJet al. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett’s esophagus . Int. J. Cancer116 ( 4 ), 584 – 591 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Colombo PE , FabbroM , TheilletC , BibeauF , RouanetP , Ray-CoquardI . Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer . Crit. Rev. Oncol. Hematol.89 ( 2 ), 207 – 216 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gloss BS , SamimiG . Epigenetic biomarkers in epithelial ovarian cancer . Cancer Lett.342 ( 2 ), 257 – 263 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Earp MA , CunninghamJM . DNA methylation changes in epithelial ovarian cancer histotypes . Genomics106 ( 6 ), 311 – 321 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ronnekleiv-Kelly SM , SharmaA , AhujaN . Epigenetic therapy and chemosensitization in solid malignancy . Cancer Treat. Rev.55 , 200 – 208 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Wang Q , WangB , ZhangYM , WangW . The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis . J. Ovarian Res.9 , 23 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Yuecheng Y , HongmeiL , XiaoyanX . Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer . Clin. Exp. Metastasis23 ( 1 ), 65 – 74 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Cardenas H , ViethE , LeeJet al. TGF-beta induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells . Epigenetics9 ( 11 ), 1461 – 1472 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ferreira P , OliveiraMJ , BeraldiEet al. Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro . Exp. Cell Res.310 ( 1 ), 99 – 104 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Montavon C , GlossBS , WartonKet al. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer . Gynecol. Oncol.124 ( 3 ), 582 – 588 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kwong J , LeeJY , WongKKet al. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer . Neoplasia8 ( 4 ), 268 – 278 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Niskakoski A , KaurS , StaffSet al. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation . Epigenetics9 ( 12 ), 1577 – 1587 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ho CM , LaiHC , HuangSH , ChienTY , LinMC , ChangSF . Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma . Eur. J. Clin. Invest.40 ( 4 ), 310 – 318 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Su HY , LaiHC , LinYWet al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway . Int. J. Cancer127 ( 3 ), 555 – 567 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Natanzon Y , GoodeEL , CunninghamJM . Epigenetics in ovarian cancer . Semin. Cancer Biol.51 , 160 – 169 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Oronsky B , RayCM , SpiraAI , TrepelJB , CarterCA , CottrillHM . A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer . Med. Oncol.34 ( 6 ), 103 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Jones PA , BaylinSB . The epigenomics of cancer . Cell128 ( 4 ), 683 – 692 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Terasawa K , SagaeS , ToyotaMet al. Epigenetic inactivation of TMS1/ASC in ovarian cancer . Clin. Cancer Res.10 ( 6 ), 2000 – 2006 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Shi H , WeiSH , LeuYWet al. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation . Cancer Res.63 ( 9 ), 2164 – 2171 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Seeber LM , Van DiestPJ . Epigenetics in ovarian cancer . Methods Mol. Biol.863 , 253 – 269 ( 2012 ).
   PubMedGoogle Scholar
• Fu S , HuW , IyerRet al. Phase 1b–2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer . Cancer117 ( 8 ), 1661 – 1669 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Matei D , FangF , ShenCet al. Epigenetic resensitization to platinum in ovarian cancer . Cancer Res.72 ( 9 ), 2197 – 2205 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Derks S , LentjesMH , HellebrekersDM , De BruineAP , HermanJG , Van EngelandM . Methylation-specific PCR unraveled . Cell Oncol.26 ( 5–6 ), 291 – 299 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Kristensen LS , HansenLL . PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment . Clin. Chem.55 ( 8 ), 1471 – 1483 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Cottrell SE , LairdPW . Sensitive detection of DNA methylation . Ann. NY Acad. Sci.983 , 120 – 130 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Laird PW . The power and the promise of DNA methylation markers . Nat. Rev. Cancer3 ( 4 ), 253 – 266 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Herman JG , GraffJR , MyohanenS , NelkinBD , BaylinSB . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands . Proc. Natl Acad. Sci. USA93 ( 18 ), 9821 – 9826 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Hernandez HG , TseMY , PangSC , ArboledaH , ForeroDA . Optimizing methodologies for PCR-based DNA methylation analysis . BioTechniques55 ( 4 ), 181 – 197 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Worsham MJ , StephenJK , ChenKMet al. Delineating an epigenetic continuum in head and neck cancer . Cancer Lett.342 ( 2 ), 178 – 184 ( 2014 ).
   PubMed Web of Science ®Google Scholar